Shopping Cart 0
Cart Subtotal
AED 0

Middle East and Africa Omega 3 Ingredients for Pharmaceuticals Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 15414

Details

Middle East and Africa omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Middle East and Africa Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA) and Alpha-Linolenic Acid (ALA)), Form (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer and Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (South Africa, Saudi Arabia, U.A.E., Kuwait and Rest of Middle East and Africa) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of Middle East and Africa omega-3 ingredients for pharmaceuticals market are:

Growing demand of functional and supplement food

Rising burden of lifestyle diseases leads the demand of Omega-3 based products

Market Players:

The key market players for Middle East and Africa omega-3 ingredients for pharmaceuticals market are listed below:

AbbVie Inc.

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Strides Pharma Science Limited

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 SOURCE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.10 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 PATENT ANALYSIS

3.1.1 DBMR ANALYSIS

3.1.2 COUNTRY LEVEL INSIGHTS

3.1.3 COMPANY BASED ANALYSIS

3.2 PRICING ANALYSIS

4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS

5 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST AND AFRICA OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET

5.1 PRICE IMPACT

5.2 IMPACT ON DEMAND

5.3 IMPACT ON SUPPLY CHAIN

5.4 STRATEGIC DECISIONS FOR MANUFACTURERS

5.5 CONCLUSION

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3

6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD

6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS

6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS

6.2 RESTRAINTS

6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS

6.2.2 HIGH COSTS OF PRODUCTS

6.3 OPPORTUNITIES

6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3

6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS

6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES

6.4 CHALLENGES

6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS

6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL

7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE

7.1 OVERVIEW

7.2 MARINE

7.3 PLANT

8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE

8.1 OVERVIEW

8.2 DOCOSAHEXAENOIC ACID (DHA)

8.3 EICOSAPENTAENOIC ACID (EPA)

8.4 ALPHA-LINOLENIC ACID (ALA)

9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM

9.1 OVERVIEW

9.2 LIQUID

9.3 DRY

10 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS

10.1 OVERVIEW

10.2 CARDIOVASCULAR DISEASES

10.2.1 HYPERLIPIDEMIA

10.2.2 STROKES

10.2.3 HYPERTENSION

10.2.4 OTHERS

10.3 CANCER

10.3.1 PROSTATE CANCER

10.3.2 BREAST CANCER

10.3.3 COLORECTAL CANCER

10.3.4 OTHERS

10.4 NEUROLOGICAL DISORDERS

10.4.1 ALZHEIMER'S DISEASE

10.4.2 COGNITIVE DISORDERS

10.4.3 BIPOLAR DISORDERS

10.4.4 SCHIZOPHRENIA

10.4.5 OTHERS

10.5 AUTOIMMUNE DISEASES

10.5.1 RHEUMATOID ARTHRITIS

10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

10.5.3 TYPE 1 DIABETES

10.5.4 OTHERS

10.6 BONE & JOINT DISORDERS

10.6.1 OSTEOPOROSIS

10.6.2 ARTHRITIS

10.6.3 OTHERS

10.7 SKIN HEALTH

10.7.1 ACNE

10.7.2 WRINKLES

10.7.3 SKIN AGING

10.7.4 OTHERS

10.8 OPHTHALMIC DISORDERS

10.8.1 DRY EYE SYNDROME

10.8.2 AGE-RELATED MACULAR DEGENERATION

10.8.3 OTHERS

10.9 OTHERS

11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE

11.1 OVERVIEW

11.2 ADULT

11.2.1 FEMALE

11.2.2 MALE

11.3 CHILDREN

12 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT

12.3 INDIRECT

13 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY

13.1 MIDDLE EAST & AFRICA

13.1.1 SOUTH AFRICA

13.1.2 UAE

13.1.3 SAUDI ARABIA

13.1.4 KUWAIT

13.1.5 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 CRODA INTERNATIONAL PLC

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 CORBION

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 DSM

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 KD PHARMA GROUP

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 STRIDES PHARMA SCIENCE LIMITED

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BASF SE

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 PHARMA MARINE AS

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 ABBVIE INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 AMARIN CORPORATION

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.10 ANI PHARMACEUTICALS, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 ASTRAZENECA

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 AVESTIA PHARMA

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 CAMBER PHARMACEUTICALS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 EPAX (A SUBSIDIARY OF PELAGIA AS)

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG)

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENT

16.16 GLAXOSMITHKLINE PLC

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 KINOMEGA BIOPHARM INC

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 NOVASEP

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 SOLUTEX

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 10 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 11 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027

FIGURE 12 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY

FIGURE 13 PATENT REGISTERED BY YEAR (2000-2020)

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET

FIGURE 15 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS)

FIGURE 16 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019

FIGURE 17 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS)

FIGURE 18 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027)

FIGURE 19 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019

FIGURE 21 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS)

FIGURE 22 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 23 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019

FIGURE 25 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS)

FIGURE 26 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027)

FIGURE 27 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 29 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS)

FIGURE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 31 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019

FIGURE 33 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS)

FIGURE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027)

FIGURE 35 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 37 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS)

FIGURE 38 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 39 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019)

FIGURE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019)

FIGURE 42 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027)

FIGURE 43 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027)

FIGURE 44 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027)

FIGURE 45 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%)


List Of Table

LIST OF TABLES

TABLE 1 THE PRICE RANGE OF OMEGA-3 INGREDIENTS

TABLE 2 COST COMPARISION OF MARINE SOURCES OF OMEGA-3 INGREDIENTS

TABLE 3 COST OF PRODUCTS

TABLE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 5 MIDDLE EAST AND AFRICA MARINE IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 6 MIDDLE EAST AND AFRICA PLANT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 8 MIDDLE EAST AND AFRICA DOCOSAHEXAENOIC ACID (DHA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 9 MIDDLE EAST AND AFRICA EICOSAPENTAENOIC ACID (EPA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 10 MIDDLE EAST AND AFRICA ALPHA-LINOLENIC ACID (ALA)IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM , 2017-2026 (USD THOUSANDS)

TABLE 12 MIDDLE EAST AND AFRICA LIQUID IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 13 MIDDLE EAST AND AFRICA DRY IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 16 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 17 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 18 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 19 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 20 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 21 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 22 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 23 MIDDLE EAST AND AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 24 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 25 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 26 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 27 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 28 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 31 GLOBA ADULT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 32 MIDDLE EAST AND AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 33 GLOBA CHILDREN IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 35 MIDDLE EAST AND AFRICA DIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 36 MIDDLE EAST AND AFRICA INDIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 37 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY COUNTRY, 2018-2027 (USD THOUSANDS)

TABLE 38 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 39 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 42 MIDDLE EAST & AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 43 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 44 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 45 MIDDLE EAST & AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 46 MIDDLE EAST & AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 47 MIDDLE EAST & AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 48 MIDDLE EAST & AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 49 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 50 MIDDLE EAST & AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 51 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 52 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 53 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 54 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 55 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 56 SOUTH AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 57 SOUTH AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 58 SOUTH AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 59 SOUTH AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 60 SOUTH AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 61 SOUTH AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 62 SOUTH AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 63 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 64 SOUTH AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 65 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 66 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 67 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 68 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 69 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 70 UAE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 71 UAE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 72 UAE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 73 UAE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 74 UAE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 75 UAE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 76 UAE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 77 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 78 UAE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 79 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 80 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 81 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 82 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 83 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 84 SAUDI ARABIA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 85 SAUDI ARABIA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 86 SAUDI ARABIA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 87 SAUDI ARABIA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 88 SAUDI ARABIA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 89 SAUDI ARABIA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 90 SAUDI ARABIA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 91 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 92 SAUDI ARABIA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 93 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 94 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 95 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 96 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 97 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 98 KUWAIT OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 99 KUWAIT NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 100 KUWAIT CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 101 KUWAIT AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 102 KUWAIT CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 103 KUWAIT BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 104 KUWAIT SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 105 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 106 KUWAIT ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 107 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 108 REST OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

AbbVie Inc.

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Strides Pharma Science Limited

Company Profile

Company Profile Title

Middle East and Africa omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Middle East and Africa Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA) and Alpha-Linolenic Acid (ALA)), Form (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer and Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (South Africa, Saudi Arabia, U.A.E., Kuwait and Rest of Middle East and Africa) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of Middle East and Africa omega-3 ingredients for pharmaceuticals market are:

Growing demand of functional and supplement food

Rising burden of lifestyle diseases leads the demand of Omega-3 based products

Market Players:

The key market players for Middle East and Africa omega-3 ingredients for pharmaceuticals market are listed below:

AbbVie Inc.

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Strides Pharma Science Limited

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 SOURCE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.10 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 PATENT ANALYSIS

3.1.1 DBMR ANALYSIS

3.1.2 COUNTRY LEVEL INSIGHTS

3.1.3 COMPANY BASED ANALYSIS

3.2 PRICING ANALYSIS

4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS

5 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST AND AFRICA OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET

5.1 PRICE IMPACT

5.2 IMPACT ON DEMAND

5.3 IMPACT ON SUPPLY CHAIN

5.4 STRATEGIC DECISIONS FOR MANUFACTURERS

5.5 CONCLUSION

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3

6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD

6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS

6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS

6.2 RESTRAINTS

6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS

6.2.2 HIGH COSTS OF PRODUCTS

6.3 OPPORTUNITIES

6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3

6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS

6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES

6.4 CHALLENGES

6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS

6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL

7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE

7.1 OVERVIEW

7.2 MARINE

7.3 PLANT

8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE

8.1 OVERVIEW

8.2 DOCOSAHEXAENOIC ACID (DHA)

8.3 EICOSAPENTAENOIC ACID (EPA)

8.4 ALPHA-LINOLENIC ACID (ALA)

9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM

9.1 OVERVIEW

9.2 LIQUID

9.3 DRY

10 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS

10.1 OVERVIEW

10.2 CARDIOVASCULAR DISEASES

10.2.1 HYPERLIPIDEMIA

10.2.2 STROKES

10.2.3 HYPERTENSION

10.2.4 OTHERS

10.3 CANCER

10.3.1 PROSTATE CANCER

10.3.2 BREAST CANCER

10.3.3 COLORECTAL CANCER

10.3.4 OTHERS

10.4 NEUROLOGICAL DISORDERS

10.4.1 ALZHEIMER'S DISEASE

10.4.2 COGNITIVE DISORDERS

10.4.3 BIPOLAR DISORDERS

10.4.4 SCHIZOPHRENIA

10.4.5 OTHERS

10.5 AUTOIMMUNE DISEASES

10.5.1 RHEUMATOID ARTHRITIS

10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

10.5.3 TYPE 1 DIABETES

10.5.4 OTHERS

10.6 BONE & JOINT DISORDERS

10.6.1 OSTEOPOROSIS

10.6.2 ARTHRITIS

10.6.3 OTHERS

10.7 SKIN HEALTH

10.7.1 ACNE

10.7.2 WRINKLES

10.7.3 SKIN AGING

10.7.4 OTHERS

10.8 OPHTHALMIC DISORDERS

10.8.1 DRY EYE SYNDROME

10.8.2 AGE-RELATED MACULAR DEGENERATION

10.8.3 OTHERS

10.9 OTHERS

11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE

11.1 OVERVIEW

11.2 ADULT

11.2.1 FEMALE

11.2.2 MALE

11.3 CHILDREN

12 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT

12.3 INDIRECT

13 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY

13.1 MIDDLE EAST & AFRICA

13.1.1 SOUTH AFRICA

13.1.2 UAE

13.1.3 SAUDI ARABIA

13.1.4 KUWAIT

13.1.5 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 CRODA INTERNATIONAL PLC

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 CORBION

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 DSM

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 KD PHARMA GROUP

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 STRIDES PHARMA SCIENCE LIMITED

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BASF SE

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 PHARMA MARINE AS

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 ABBVIE INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 AMARIN CORPORATION

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.10 ANI PHARMACEUTICALS, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 ASTRAZENECA

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 AVESTIA PHARMA

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 CAMBER PHARMACEUTICALS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 EPAX (A SUBSIDIARY OF PELAGIA AS)

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG)

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENT

16.16 GLAXOSMITHKLINE PLC

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 KINOMEGA BIOPHARM INC

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 NOVASEP

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 SOLUTEX

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 10 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 11 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027

FIGURE 12 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY

FIGURE 13 PATENT REGISTERED BY YEAR (2000-2020)

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET

FIGURE 15 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS)

FIGURE 16 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019

FIGURE 17 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS)

FIGURE 18 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027)

FIGURE 19 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019

FIGURE 21 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS)

FIGURE 22 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 23 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019

FIGURE 25 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS)

FIGURE 26 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027)

FIGURE 27 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 29 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS)

FIGURE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 31 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019

FIGURE 33 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS)

FIGURE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027)

FIGURE 35 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 37 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS)

FIGURE 38 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 39 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019)

FIGURE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019)

FIGURE 42 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027)

FIGURE 43 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027)

FIGURE 44 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027)

FIGURE 45 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%)


List Of Table

LIST OF TABLES

TABLE 1 THE PRICE RANGE OF OMEGA-3 INGREDIENTS

TABLE 2 COST COMPARISION OF MARINE SOURCES OF OMEGA-3 INGREDIENTS

TABLE 3 COST OF PRODUCTS

TABLE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 5 MIDDLE EAST AND AFRICA MARINE IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 6 MIDDLE EAST AND AFRICA PLANT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 8 MIDDLE EAST AND AFRICA DOCOSAHEXAENOIC ACID (DHA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 9 MIDDLE EAST AND AFRICA EICOSAPENTAENOIC ACID (EPA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 10 MIDDLE EAST AND AFRICA ALPHA-LINOLENIC ACID (ALA)IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM , 2017-2026 (USD THOUSANDS)

TABLE 12 MIDDLE EAST AND AFRICA LIQUID IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 13 MIDDLE EAST AND AFRICA DRY IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 16 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 17 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 18 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 19 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 20 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 21 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 22 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 23 MIDDLE EAST AND AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 24 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 25 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 26 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 27 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 28 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 31 GLOBA ADULT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 32 MIDDLE EAST AND AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 33 GLOBA CHILDREN IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 35 MIDDLE EAST AND AFRICA DIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 36 MIDDLE EAST AND AFRICA INDIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 37 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY COUNTRY, 2018-2027 (USD THOUSANDS)

TABLE 38 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 39 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 42 MIDDLE EAST & AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 43 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 44 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 45 MIDDLE EAST & AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 46 MIDDLE EAST & AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 47 MIDDLE EAST & AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 48 MIDDLE EAST & AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 49 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 50 MIDDLE EAST & AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 51 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 52 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 53 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 54 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 55 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 56 SOUTH AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 57 SOUTH AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 58 SOUTH AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 59 SOUTH AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 60 SOUTH AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 61 SOUTH AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 62 SOUTH AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 63 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 64 SOUTH AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 65 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 66 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 67 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 68 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 69 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 70 UAE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 71 UAE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 72 UAE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 73 UAE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 74 UAE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 75 UAE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 76 UAE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 77 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 78 UAE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 79 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 80 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 81 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 82 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 83 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 84 SAUDI ARABIA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 85 SAUDI ARABIA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 86 SAUDI ARABIA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 87 SAUDI ARABIA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 88 SAUDI ARABIA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 89 SAUDI ARABIA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 90 SAUDI ARABIA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 91 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 92 SAUDI ARABIA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 93 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 94 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 95 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 96 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 97 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 98 KUWAIT OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 99 KUWAIT NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 100 KUWAIT CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 101 KUWAIT AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 102 KUWAIT CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 103 KUWAIT BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 104 KUWAIT SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 105 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 106 KUWAIT ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 107 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 108 REST OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

AbbVie Inc.

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Strides Pharma Science Limited